Wall Street analysts expect Affimed NV (NASDAQ:AFMD) to report earnings per share (EPS) of ($0.16) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Affimed’s earnings. The lowest EPS estimate is ($0.21) and the highest is ($0.11). Affimed also reported earnings of ($0.16) per share in the same quarter last year. The firm is expected to report its next earnings results on Wednesday, August 14th.
On average, analysts expect that Affimed will report full year earnings of ($0.28) per share for the current financial year, with EPS estimates ranging from ($0.62) to $0.36. For the next fiscal year, analysts forecast that the company will post earnings of ($0.32) per share, with EPS estimates ranging from ($0.79) to $0.91. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Affimed.
Affimed (NASDAQ:AFMD) last issued its earnings results on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.19. The business had revenue of $12.89 million for the quarter, compared to analyst estimates of $6.77 million. Affimed had a negative return on equity of 23.61% and a negative net margin of 29.04%.
Large investors have recently added to or reduced their stakes in the business. D. E. Shaw & Co. Inc. purchased a new position in Affimed in the fourth quarter valued at about $36,000. Lindbrook Capital LLC purchased a new position in Affimed in the fourth quarter valued at about $38,000. Bourgeon Capital Management LLC purchased a new stake in shares of Affimed during the first quarter worth about $42,000. Sigma Planning Corp purchased a new stake in shares of Affimed during the first quarter worth about $46,000. Finally, Jane Street Group LLC purchased a new stake in shares of Affimed during the first quarter worth about $72,000. 37.50% of the stock is currently owned by institutional investors.
Shares of AFMD traded up $0.14 during trading hours on Wednesday, hitting $3.10. The stock had a trading volume of 1,133,310 shares, compared to its average volume of 751,537. The company has a current ratio of 3.17, a quick ratio of 3.16 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $163.46 million, a P/E ratio of -8.16 and a beta of 3.08. Affimed has a 12-month low of $1.40 and a 12-month high of $7.35.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Further Reading: What is total return in investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.